Roche Holding AG (RHHVF)

OTCMKTS · Delayed Price · Currency is USD
327.61
+8.92 (2.80%)
Jun 26, 2025, 10:22 AM EDT
14.92%
Market Cap 258.17B
Revenue (ttm) 68.85B
Net Income (ttm) 9.13B
Shares Out n/a
EPS (ttm) 11.38
PE Ratio 28.26
Forward PE 12.82
Dividend 10.98 (3.40%)
Ex-Dividend Date Mar 27, 2025
Volume 55
Average Volume 7,671
Open 332.39
Previous Close 318.69
Day's Range 321.03 - 332.39
52-Week Range 266.59 - 354.19
Beta 0.17
RSI 48.14
Earnings Date Jul 24, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHVF
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...

3 days ago - Benzinga

Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combinati...

6 days ago - GlobeNewsWire

Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio...

6 days ago - Business Wire

Genentech Provides Update on Phase III Verona Study

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...

10 days ago - Business Wire

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

10 days ago - WSJ

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease - - Prasinezumab is a potential first-in-clas...

10 days ago - Benzinga

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a...

10 days ago - Business Wire

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease Prasinezumab is a potential first-in-class a...

10 days ago - Benzinga

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-...

10 days ago - GlobeNewsWire

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscu...

11 days ago - GlobeNewsWire

Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training (1) PiaSky® (crovalimab for injection) has the p...

15 days ago - Benzinga

Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems

JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has completed...

15 days ago - GlobeNewsWire

$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.

The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansi...

16 days ago - GlobeNewsWire

Green Steel Industry Report 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.

The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric a...

16 days ago - GlobeNewsWire

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

Chugai Pharmaceutical Co. Ltd . (OTC: CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE: LLY) oral obesity pill , orforglipron. Roche Holdings AG (OTC: R...

17 days ago - Benzinga

Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death com...

20 days ago - Reuters

Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature st...

22 days ago - GlobeNewsWire

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC: RHHBY) Tecentriq (atezoliz...

22 days ago - Benzinga

Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

23 days ago - WSJ